Channel Therapeutics Corporation Common Stock (AMEX:CHRO)

Real-time price: | Most recent change:0.00%

Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. Channel Therapeutics Corporation, formerly known as Chromocell Therapeutics Corporation, is based in FREEHOLD, N.J....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 5 September 2026

Blog+More

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and governments.

Jonah Whanau

2019-11-15 13:34:00 Friday ET

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and governments.

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and go

+See More

Fed Chair Janet Yellen confirms with her successor Jerome Powell the final interest rate hike in December 2017.

Joseph Corr

2017-12-14 12:41:00 Thursday ET

Fed Chair Janet Yellen confirms with her successor Jerome Powell the final interest rate hike in December 2017.

Federal Reserve raises the interest rate by 25 basis points to the target range of 1.25% to 1.5% as FOMC members revise up their GDP estimate from 2% to 2.5

+See More

Investing in stocks is the best way for people to become self-made millionaires.

James Campbell

2019-06-25 10:34:00 Tuesday ET

Investing in stocks is the best way for people to become self-made millionaires.

Investing in stocks is the best way for people to become self-made millionaires. A recent Gallup poll indicates that only 37% of young Americans below the a

+See More

Corporate America uses Trump tax cuts and offshore cash stockpiles primarily to fund share repurchases for better stock market valuation.

Jacob Miramar

2019-02-11 09:37:00 Monday ET

Corporate America uses Trump tax cuts and offshore cash stockpiles primarily to fund share repurchases for better stock market valuation.

Corporate America uses Trump tax cuts and offshore cash stockpiles primarily to fund share repurchases for better stock market valuation. Share repurchases

+See More

The world now faces an economic inequality crisis with few policy options.

Daisy Harvey

2018-01-04 07:36:00 Thursday ET

The world now faces an economic inequality crisis with few policy options.

The world now faces an economic inequality crisis with few policy options. Some recent U.S. Federal Reserve data suggest that both income and wealth inequal

+See More

Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

John Fourier

2026-10-31 12:38:00 Saturday ET

Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Today tech titans and billionaires continue to reshape global pharmaceutical investments for both better healthspan and longer lifespan. We discuss, desc

+See More